Roche Innovation Center Copenhagen A/S

LIfT BioSciences appoints Dr Bo Rode Hansen and Dr Marco Gottardis to its Board of Directors London, 21 December 2023 – LIfT BioSciences, (‘LIfT’ or ‘the Company’), a rapidly emerging biotech company bringing to market a first-in-class allogeneic innate cell therapy, today announces the appointments of Dr Bo Rode Hansen PhD, MBA and Dr Marco Gottardis, PhD as Non-Executive Directors of its Board. Bo brings over two decades of transformational leadership experience involving general management, R&D, BD, financing, IPO and M&A in the biotech and pharmaceutical industries. He currently advises Novo Seeds (Novo Holdings), a life science investment company and consults for different life science, biotech, and investment companies. He previously served as the CEO and President of Scandion Oncology A/S, a Danish cancer drug resistance company. Prior to this, Bo held several leadership positions including CEO & Founding President of Genevant Sciences, Global Head of RNA Therapeutics at Roche, GM (CEO) of Roche Innovation Centre Copenhagen and Vice President of Santaris Pharma A/S. He holds a MSc and PhD in Biochemistry from the University of Copenhagen and an Executive MBA from Henley Business School. Marco joins the Board with over 38 years of experience working in translational cancer research, having worked over multiple drug approvals in his career. In 2023, he retired from his role as VP of Oncology and Innovation at Janssen, prior to which he held the role of Prostate DAS Leader. Before his time at Janssen, Marco served as Executive Director of Oncology and Immuno-Oncology Research, and co-leader of the Oncology Discovery Group at Bristol Myers Squibb, where he led multiple scientific teams covering diverse target areas. Marco holds a PhD from the University of Wisconsin and a BSc from Columbia University. Alex Blyth, Chief Executive Officer of LIfT BioSciences commented: “On behalf of the Board, I’m delighted to welcome both Bo and Marco onto our Board of Directors as key hires for LIfT’s next phase as we move into license deals. Bo is a highly respected bioentrepreneur and driver of corporate innovation who has successfully taken early-stage companies through to successful exits. Bo understands how to structure innovative deals with, and in, big pharma to drive successful outcomes for both parties – having sat both sides of the fence. Marco is a highly respected scientific leader who has been instrumental in bringing about breakthrough innovation in BMS and JnJ. Marco knows how to create the scientific case to bring about deals that are transformative for both entities. Both will prove invaluable in our mission to redefine what is possible across oncology, immunology, neurology and AMR through our unique Immuno-Modulatory Alpha Neutrophil technology.” Dr Bo Rode Hansen, Non-Executive Director of the Board commented: “I’m pleased to join LIfT at this pivotal time, as we look to move our allogeneic first-in-class neutrophil-based cell therapies into clinical development. I look forward to collaborating with Alex and the rest of the Board.” Dr Marco Gottardis, Non-Executive Director of the Board commented: “I’m delighted to be joining LIfT Biosciences, a company at the forefront of innovative cancer therapies. I look forward to contributing to the Company's continuously developing ground-breaking research, as we work towards entering clinical trials with the goal of developing affordable, effective treatments for patients.” About LIfT BioSciences LIfT BioSciences is a biotech bringing to market a first-in-class alpha neutrophil cell therapy that overcomes the limitations of current therapies in solid tumours by destroying tumours both directly and indirectly. LIfT’s Immunomodulatory Alpha Neutrophils (IMANs) turn the tumour microenvironment against the tumour as they recruit the rest of the immune system to destroy the tumour to give a durable response and lasting immunity. The patented breakthrough N-LIfT platform is produced from a patented process using exceptional stem cells (iPSC or HSC), a proprietary enhancement media and genetic engineering (e.g. CARs). The resulting CAR-IMAN cells give cancer patients potentially hundreds of times the cancer killing ability they naturally possess. The company is working with a range of pharmaceutical license partners across oncology, immunology, neurology and AMR to develop a portfolio of immune-modulatory. LIfT is committed to delivering complete remission in high unmet need solid tumours before the decade is out. LIfT BioSciences was founded by Alex Blyth following the death of his mother to pancreatic cancer. See www.liftbiosciences.com. Further information Investors & Media: Alex BlythICR ConsiliumMary-Jane Elliott, Namrata Taak, Lindsey Neville+44 (0)7718 759116ablyth@LIfTBioSciences.comliftbiosciences@consilium-comms.com

LONDON--( BUSINESS WIRE )--Silence Therapeutics plc, Nasdaq: SLN (“Silence” or the “Company”), an experienced and innovative biotechnology company committed to transforming people’s lives by silencing diseases through precision engineered medicines, today announced Curtis Rambaran, MD, previously Silence’s Vice President, Head of Clinical Science, has been promoted to Chief Medical Officer, and Marie Wikström Lindholm, PhD, previously Silence’s Senior Vice President, Head of Molecular Design, has been promoted to Chief Scientific Officer, effective immediately. “I want to congratulate Curtis and Marie on their well-deserved promotions,” said Steven Romano, MD, Head of Research and Development at Silence. “Both have been instrumental to our clinical and scientific successes to date. Curtis’ broad experience leading successful early and late-stage development programs combined with his background in cardiovascular medicine will be invaluable to Silence’s next phase of growth. With our expanding mRNAi GOLD™ platform programs and commitment to advancing scientific research, I am also looking forward to continuing to collaborate closely with Marie. Her extensive work in oligonucleotide therapeutics is impressive and we are very fortunate to have her leading our efforts to innovate and further expand our footprint as a global siRNA leader.” About Curtis Rambaran, MD Curtis Rambaran joined Silence Therapeutics as VP and Head of the Clinical Science group in January 2021. He has 15 years’ experience in drug development across large pharma, medium sized pharma and recently biotech, spanning early and late-stage programs in cardiovascular, respiratory and rare diseases. Curtis joined the Respiratory Translational Medicine team at GlaxoSmithKline (GSK) in 2009 developing first in human and experimental medicine studies for novel oral and inhaled cardiopulmonary assets. He then moved to late phase development to work on several cardiovascular outcome studies (CVOTs) with novel anti-inflammatory MOA including LpPLA2 and p38 MAPK inhibitors. Following this, he became European Head of Translational Medicine and Clinical Pharmacology at Daiichi Sankyo UK, transitioning a year later to work with the New Jersey-based team in the US, leading early development programs across cardio-renal and rare diseases. This included human induced pluripotent stem cells for heart failure, NaPi-IIb inhibition for hyperphosphatemia in chronic kidney disease and an RNA antisense oligonucleotide for Duchenne Muscular Dystrophy. Prior to joining industry, Curtis received a prestigious Wellcome Trust Cardiology Research Fellowship at King’s College University of London, followed by a specialist training program in Cardiovascular Medicine and Clinical Pharmacology at Guy’s & St Thomas’ Hospital London, UK. Preceding this, he completed an Internal Medicine residency in Yorkshire, UK after graduating with a medical degree from the University of the West Indies. He has led several academic-industry collaborations and published in peer-reviewed journals on vascular structure and function, cardiac safety, hypertension and clinical pharmacology. About Marie Wikström Lindholm, PhD Marie Wikström Lindholm joined Silence in December 2017. She has more than 15 years’ experience with oligonucleotide therapeutics, starting with Santaris Pharma A/S, Denmark, working on locked nucleic acid (LNA) oligonucleotide drug discovery from molecule design through in vitro screening, in vivo activity and metabolism studies, and finally a role as lipid metabolism expert. When Santaris was acquired by Roche in 2014, she was appointed Expert Scientist in Discovery Technology and Head of Targeted Delivery of oligonucleotide conjugates. She was also scientific coordinator for the LNA work in two large EU-funded FP7 programs (AtheroBCell and AtheroFlux). Before the transition to industry, she had an international academic career in experimental cardiovascular research starting with a PhD from Uppsala University. She has authored over 60 patents and peer-reviewed scientific publications, many in the fields of oligonucleotide drug design, safety, and function. About Silence Therapeutics Silence Therapeutics is developing a new generation of medicines by harnessing the body's natural mechanism of RNA interference, or RNAi, to inhibit the expression of specific target genes thought to play a role in the pathology of diseases with significant unmet need. Silence's proprietary mRNAi GOLD™ platform can be used to create siRNAs (short interfering RNAs) that precisely target and silence disease-associated genes in the liver, which represents a substantial opportunity. Silence's wholly owned product candidates include zerlasiran designed to address the high and prevalent unmet medical need in reducing cardiovascular risk in people born with high levels of lipoprotein(a) and SLN124 designed to address hematological diseases. Silence also maintains ongoing research and development collaborations with AstraZeneca, Mallinckrodt Pharmaceuticals, and Hansoh Pharma, among others. For more information, please visit https://www.silence-therapeutics.com/ . Forward-Looking Statements Certain statements made in this announcement are forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and other securities laws, including with respect to the Company’s cash runway and forecast operating cash flow, the Company’s clinical and commercial prospects, regulatory approvals of the Company’s product candidates, potential partnerships or collaborations or payments under new and existing collaborations, the initiation or completion of the Company’s clinical trials and the anticipated timing or outcomes of data reports from the Company’s clinical trials. These forward-looking statements are not historical facts but rather are based on the Company's current assumptions, beliefs, expectations, estimates and projections about its industry. Words such as “anticipate,” “expect,” “intend,” “plan,” “believe,” “seek,” “estimate,” and similar expressions are intended to identify forward-looking statements. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties, and other factors, some of which are beyond the Company's control, are difficult to predict, and could cause actual results to differ materially from those expressed or forecasted in the forward-looking statements, including those risks identified in the Company’s most recent Admission Document and its Annual Report on Form 20-F filed with the U.S. Securities and Exchange Commission on March 15, 2023. The Company cautions security holders and prospective security holders not to place undue reliance on these forward-looking statements, which reflect the view of the Company only as of the date of this announcement. The forward-looking statements made in this announcement relate only to events as of the date on which the statements are made. The Company will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances, or unanticipated events occurring after the date of this announcement except as required by law or by any appropriate regulatory authority.

NEW YORK, Nov. 8, 2023 /PRNewswire/ -- Genetic information collected from seemingly healthy tissue near lung tumors may be a better predictor of whether cancer will come back after treatment than analysis of the tumors themselves, according to new research led by NYU Langone Health and its Perlmutter Cancer Center. The new study focuses on lung adenocarcinoma, a cancer that forms in alveolar epithelial cells and accounts for about a third of all lung cancers in the United States, according to the U.S. Centers for Disease Control and Prevention. Most patients are cured if tumors are surgically removed early in the disease's progression, but residual cancer cells regrow in about 30% of cases and can lead to death. Consequently, experts have long searched for biomarkers, or predictors of recurrence, which might prompt more aggressive initial treatment. The study included 147 men and women treated for early-stage lung cancer. It explored the utility value of the transcriptome, the complete set of RNA molecules that tell cells what proteins to make. Analysis of RNA collected from apparently healthy tissue adjacent to tumor cells accurately predicted that cancer would recur 83% of the time, while RNA from tumors themselves was only informative 63% of the time. "Our findings suggest that the pattern of gene expression in apparently healthy tissue might serve as an effective and until now elusive biomarker to help predict lung-cancer recurrence in the earliest stages of the disease," said study co-lead author Igor Dolgalev, PhD. Publishing online Nov. 8 in the journal Nature Communications, the investigation is the largest to date comparing genetic material from tumors and adjacent tissue and for their ability to predict recurrence, says Dolgalev, an assistant professor in the Department of Medicine at NYU Grossman School of Medicine and a member of Perlmutter Cancer Center. For the study, the research team collected almost 300 tumor and healthy tissue samples from lung cancer patients. The study investigators then sequenced the RNA from each sample and fed these data, along with whether or not recurrence occurred within five years of surgery, into an artificial intelligence algorithm. This program used a technique called "machine learning" to build mathematical models that estimated recurrence risk. The findings revealed that the expression of genes associated with inflammation, or heightened immune-system activity, in adjacent, apparently normal lung tissue, was especially useful for making predictions. This defensive reaction, the study authors say, should not be present in tissue that is truly healthy and may be an early warning sign of disease. "Our results suggest that seemingly normal tissue that sits close to a tumor may not be healthy after all," said study co-lead author Hua Zhou, PhD, a bioinformatician at NYU Grossman and a member of Perlmutter Cancer Center. "Instead, escaped tumor cells might be triggering this unexpected immune response in their neighbors." "Immunotherapy, which bolsters the body's immune defenses, might therefore help combat tumor growth before it becomes visible to traditional methods of detection," added study co-senior author and cancer biologist Aristotelis Tsirigos, PhD. Tsirigos, a professor in the Department of Pathology at NYU Grossman and a member of Perlmutter Cancer Center, cautions that the investigation worked backwards, training the computer program using cases already known to have had disease return. As a result, the study team next plans to use the program to prospectively assess recurrence risk in patients newly treated for early-stage lung cancer, says Tsirigos, who is also director of NYU Langone's Applied Bioinformatics Laboratories. Funding for the study was provided by National Institutes of Health grants R37CA244775 and U01CA214195. Further support was provided by the American Association for Cancer Research Grant and the Roche Access to Distinguished Scientists Programme. NYU Langone has a patent pending (TSI03-02PRO) for diagnostic tools developed from this approach. Tsirigos, Dolgalev, Zhou, study co-senior investigators Harvey Pass, MD; Andre Moreira, MD; and Leopoldo Segal, MD; as well as NYU Langone may benefit financially from this patent. The terms and conditions of these relationships are being managed in accordance with the policies of NYU Langone Health. In addition to Dolgalev, Zhou, and Tsirigos, other NYU Langone researchers involved in the study are Hortense Le, MS; Theodore Sakellaropoulos, PhD; Nina Shenker-Tauris, MS; Nicolas Coudray, PhD; Varshini Vasudevaraja, MS; Kelsey Zhu, BS; Chandra Goparaju, PhD; Yonghua Li, MD, PhD; Imran Sulaiman, MD; Jun-Chieh Tsay, MD; Peter Meyn; Hussein Mohamed, PE; Iris Sydney, BA; Sitharam Ramaswami, PhD; Navneet Narula, MD; Luis Chiriboga, PhD; Adriana Heguy, PhD; Thales Papagiannakopoulos, PhD; Matija Snuderl, MD; Salman Punekar, MD; Vamsidhar Velcheti, MD; J.T. Poirier, PhD; Benjamin G. Neel, MD, PhD; and Kwok-Kin Wong, MD, PhD. Additional coauthors are Anna Yeaton, BS, at the Broad Institute of MIT and Harvard University in Cambridge, Mass.; Ruth Kulicke, BS; Fred Davis, MD; Nicolas Stransky, PhD; and Gromoslaw Smolen, PhD; at Celsius Therapeutics, also in Cambridge; and Wei-Yi Cheng, PhD, and James Cai, PhD; at Roche Innovation Center in New York City. Media Inquiries: Shira Polan Phone: 212-404-4279 [email protected] SOURCE NYU Grossman School of Medicine and NYU Langone Health